Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the overall dermatology drug market (which includes atopic dermatitis, urticaria, and psoriasis) will experience modest growth of 8% per year through 2008. According to the new DR Pipeline Report entitled Dermatology Pipeline Analysis: A Market with Room to Grow, the psoriasis market will experience the most growth, with the atopic dermatitis market seeing more modest growth. The urticaria market will actually experience a decline.

The report also finds that Amgen will become a significant emerging player in the dermatological drug market with Enbrel for the treatment of adults with moderate-to-severe chronic plaque psoriasis.

"Prior to 2004, Amgen did not compete in the dermatology market segment. However, in April of this year, the FDA approved the company's application for the extended use of its existing blockbuster product, Enbrel. The FDA approved Enbrel for extended use in the treatment of adults with moderate-to-severe chronic plaque psoriasis, enabling Amgen to enter the dermatology market," said Heather Martin, analyst at Decision Resources. "By 2008, as a result of this approval, Enbrel should gain the third-highest market share in the dermatology indications of psoriasis, atopic dermatitis and urticaria."

The overall dermatological disease market constitutes the ninth-largest segment of the global pharmaceutical market.

About DR Pipeline Reports from Decision Resources

DR Pipeline Reports is a series of comprehensive reports that focuses on pharmaceutical and biotech company drug development and commercialization strategies. Geared toward business development decision makers in the pharmaceutical, biotech, and financial industries, the DR Pipeline Reports expose major players in a therapeutic market and, more importantly, shed light on the emerging players that could significantly impact the current market once their pipelines are launched.

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Physicians and Managed Care Pharmacy Directors at Odds Over Fixed-Dose Combination Agents for Metabolic Syndrome

View Now